Clinical trials: Retinal Vascular
Diabetic Macular Edema
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of Chinese patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- KINGLET (NCT04058067)
- Testing
- Brolucizumab, Aflibercept
- Where
- 24 sites in China
- Volunteers
- 266 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Diabetic Retinopathy
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME).
- Trial name
- NCT05607810
- Testing
- ADVM-022
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Adverum Biotechnologies, Inc.
Macular Edema, Central Retinal Vein Occlusion
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
This study evaluates the efficacy and safety of Conbercept ophthalmic injection. This is a multi-center, randomized, double-masked, placebo-controlled phase III clinical study.
- Trial name
- CRAVE (NCT03223714)
- Testing
- Conbercept Ophthalmic Injection
- Where
- 27 sites in China
- Volunteers
- 242 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Diabetic Macular Edema, Branch Retinal Vein Occlusion
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
- Trial name
- CLEAN (NCT05127525)
- Testing
- IRX-101, Control
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）
A randomized, double-blind, parallel controlled, multicenter clinical trial to compare the efficacy and safety of LY09004 and EYLEA in the Treatment of Wet Age-related Macular Degeneration（wAMD)
- Trial name
- NCT04572698
- Testing
- LY09004, Eylea
- Volunteers
- 416 people
- Sponsor
- Luye Pharma Group Ltd.
Diabetic Retinopathy
Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients
In this clinical study the Notal Vision Home OCT (NVHO) Monitoring System will be used to evaluate the ability of patients diagnosed with DME to perform sequential self-images of their eyes with the self-operated NVHO device in a…
- Trial name
- NCT05417152
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Notal Vision Inc.
Macular Edema Secondary to Branch Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- Blossom (NCT01976338)
- Testing
- Ranibizumab 0.5 mg
- Where
- 33 sites in China, Hong Kong and 4 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy, DR
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic…
- Trial name
- NCT05296447
- Testing
- Standard of Care, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- AbbVie
Diabetic Retinopathy, HIV
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01591902
- Testing
- Tesamorelin
- Where
- 24 sites in United States
- Volunteers
- 129 people
- Sponsor
- Theratechnologies
Diabetic Retinopathy
A Study of PER-001 in Participants With Diabetic Retinopathy
This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.
- Trial name
- NCT06003751
- Testing
- PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Perfuse Therapeutics, Inc.
Diabetic Retinopathy
Computer-based Screening for Diabetic Retinopathy
The study is an Observational, Phase 0 designed to establish that the risk for diabetic retinopathy assigned by the RiskAnalyzer improves the reading accuracy and consistency of any reader and it decreases the inter-reader…
- Trial name
- NCT01614327
- Where
- 2 sites in United States
- Volunteers
- 19,199 people
- Sponsor
- VisionQuest Biomedical LLC
Age - Related Macular Degeneration, Diabetic Retinopathy
A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools
The CLEAR study is testing the level of agreement between visual acuity and Amsler grid testing using a mobile vision testing application, Checkup Study, and standard in office methods.
- Conditions
- Age - Related Macular Degeneration, Diabetic Retinopathy, Metamorphopsia
- Trial name
- CLEAR (NCT02871817)
- Testing
- Paxos Checkup Study Mobile Medical Application
- Where
- 12 sites in United States
- Volunteers
- 143 people
- Sponsor
- Digisight Technologies, Inc.